Tuesday, December 7, 2021

    Latest Posts

    FDA reviews Merckcovid’s treatment “as soon as possible”

    Anthony Fauci, director of the National Institutes of Health (NIH) National Institute of Allergic Infectious Diseases, said before the Senate Health, Education, Labor and Pension hearings, the latest information from federal authorities on the fight against COVID-19. Testify to find out. May 11, 2021 at the Dirksen Senate Office Building in Washington, DC.

    Jim Lo Skullzo | Getty Images

    Dr. Anthony Fauci, Chief Medical Advisor of the White House, said on Friday that the Food and Drug Administration Merck “As soon as possible” with Ridgeback Biotherapeutics’ new Covid oral antiviral drug in the hope of issuing an emergency use authorization.

    Both companies said Their antivirals Treatment with molnupiravir reduced the risk of hospitalization or death in mild or moderate Covid unvaccinated patients by approximately 50%. In a phase 3 clinical trial enrolling 775 participants who took either molnupiravir or placebo, eight who received placebo died within 29 days. None of the participants who took molnupiravir died, according to data released on Friday.

    “We need to make sure that the FDA examines the data very carefully and gives them time to make certain decisions for emergency use authorization,” Fauci told CNBC.Closing bell.. “So I don’t want to get ahead of them. I can’t predict when, but there’s one thing I can say. They’ll do it as soon as possible.”

    Merck and Ridgeback Biotherapeutics also stated that 7.3% of Mornupyrabir recipients in the Phase 3 trial were hospitalized within 29 days and 14.1% of placebo recipients were hospitalized or died. All participants had at least one health condition that increased the likelihood of more serious Covid symptoms.

    With an emergency use authorization from the FDA, molnupiravir will be the first oral antiviral drug to fight Covid. The United States has agreed to purchase 1.7 million courses of Molnupiravir. Jeff Seiens, the White House’s coronavirus response coordinator, told reporters at a briefing on Friday that the government had the option to buy more doses if the drug was approved.

    Merck predicts that 10 million courses in Molnupiravir will be available by the end of 2021.

    When asked if Molnupiravir was ultimately reserved only for unvaccinated people, Forch said he wanted to avoid speculation before the FDA made the final decision.Fully vaccinated people can be especially infected with Covid As the effectiveness of the vaccine decreasesHowever, they retain a high degree of protection against severe illness and death.

    “I shouldn’t precede the FDA’s approval of it,” Forch said. “But if you’re infected, you’re infected. It doesn’t really matter if you’re vaccinated.”

    FDA reviews Merckcovid’s treatment “as soon as possible”

    Source link FDA reviews Merckcovid’s treatment “as soon as possible”

    The post FDA reviews Merckcovid’s treatment “as soon as possible” appeared first on Eminetra.

    Latest Posts

    Don't Miss

    Stay in touch

    To be updated with all the latest news, offers and special announcements.